Arete Wealth Advisors LLC lowered its stake in Medtronic plc (NYSE:MDT - Free Report) by 18.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 27,092 shares of the medical technology company's stock after selling 6,123 shares during the quarter. Arete Wealth Advisors LLC's holdings in Medtronic were worth $2,433,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also added to or reduced their stakes in MDT. Fortitude Family Office LLC bought a new stake in Medtronic during the third quarter worth about $27,000. Darwin Wealth Management LLC bought a new stake in Medtronic in the 3rd quarter worth approximately $27,000. Highline Wealth Partners LLC purchased a new stake in Medtronic in the third quarter worth approximately $27,000. J. Stern & Co. LLP bought a new position in Medtronic during the third quarter valued at approximately $30,000. Finally, True Wealth Design LLC raised its stake in shares of Medtronic by 1,793.3% during the third quarter. True Wealth Design LLC now owns 568 shares of the medical technology company's stock worth $51,000 after acquiring an additional 538 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company's stock.
Shares of MDT opened at $83.60 on Wednesday. Medtronic plc has a fifty-two week low of $75.96 and a fifty-two week high of $92.68. The firm's 50-day simple moving average is $88.13 and its two-hundred day simple moving average is $85.01. The stock has a market cap of $107.20 billion, a PE ratio of 25.57, a price-to-earnings-growth ratio of 2.38 and a beta of 0.82. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.39 and a current ratio of 1.84.
Medtronic (NYSE:MDT - Get Free Report) last posted its quarterly earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.01. The company had revenue of $8.40 billion for the quarter, compared to the consensus estimate of $8.27 billion. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The firm's quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.25 EPS. Analysts anticipate that Medtronic plc will post 5.45 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, January 10th. Investors of record on Friday, December 27th will be paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date of this dividend is Friday, December 27th. Medtronic's payout ratio is 85.63%.
MDT has been the topic of several recent research reports. Oppenheimer raised their price target on Medtronic from $92.00 to $94.00 and gave the stock a "market perform" rating in a research report on Wednesday, August 21st. JPMorgan Chase & Co. lowered their price target on shares of Medtronic from $99.00 to $96.00 and set a "neutral" rating for the company in a report on Friday, November 15th. Stifel Nicolaus boosted their price objective on shares of Medtronic from $85.00 to $87.00 and gave the company a "hold" rating in a research report on Wednesday, August 21st. UBS Group upgraded shares of Medtronic from a "sell" rating to a "neutral" rating and increased their target price for the stock from $76.00 to $90.00 in a report on Thursday, August 15th. Finally, Truist Financial boosted their price target on Medtronic from $90.00 to $93.00 and gave the company a "hold" rating in a report on Monday, October 14th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $95.27.
View Our Latest Research Report on Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.